A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib.

Trial Profile

A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2015

At a glance

  • Drugs Brivanib alaninate (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BRISK-APS
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 May 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Jun 2012 Actual initiation date changed from May 2010 to Jan 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top